Author Archives: admin


Stem Cell Clinic > Articles by: admin

Cell Therapy Packaging Products and Services Market worth $1.25 Billion by 2030 – Exclusive Report by Ins – Benzinga

By Stem Cell Treatment

JERSEY CITY, N.J., June 15, 2022 /PRNewswire/ --InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Cell Therapy Packaging Products and Services Market (Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies, and Other ATMPs), Package Engineering Design (Primary Packaging and Secondary Packaging), Scale of Operation (Clinical and Commercial)) By Trends, Industry Competition Analysis, Revenue and Forecast Till 2030"

According to the latest research by InsightAce Analytic, the global cell therapy packaging products and services market is expected to reach US$ 1,252.14 Million in 2030, recording a promising CAGR of 20.32% during the period of 2022-2030.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1265

Cell therapy aims to modify genetic material to treat different chronic diseases. Cell and gene therapy is the most significant medical advance in recent history. The increasing investments by key players in the development of promising therapies and advanced packaging technologies are anticipated to fuel the market growth over the forecast period.

Biopharmaceutical companies are investing in developing and manufacturing new customizable "patient-centered medicine" and modernizing their supply chains. Although biopharmaceutical firms' primary focus is on the drug product (DP) research and production and delivery methods (e.g., syringes), packaging and labelling are crucial to ensuring product quality and efficacy. The packaging of cell and gene therapy products must maintain closure integrity and product stability and allow simple access to the product while remaining functional during heat and mechanical loads experienced. The packaging must be designed to endure cryogenic temperatures without compromising the quality of the biological material or its longevity. For instance, In February 2022, Sharp, a leading provider in contract packaging and clinical supply services, has designed new purpose-built production suites to fulfil the rising demand from producers of gene treatments for dedicated and specialized packaging capacity. The innovative secondary packaging by Sharp aims to give an appropriate environment for tackling the challenges of gene treatments, notably at low temperatures and distribution in cold and ultra-cold supply chains. In summary, packaging technology and engineering, graphics, and labelling design are vital components of the development and marketing of gene and cell therapy programs.

Major driving factors of the cell therapy packaging products and services market are the increasing need for cell therapies, advancements in packaging and labelling, high prevalence of cancer diseases. Furthermore, advanced medical technologies, the rising trend of outsourcing in the healthcare industry, and the ongoing efforts of service providers to further improve their portfolios are enhancing the growth of the cell therapy packaging products and services market. However, the high cost of manufacturing systems, lack of standard therapy protocols, and complex procedures are restraining the growth of this market.

Geographically, the North America region is the primary revenue holder of this market due to rising awareness about cell and gene therapies, increasing government investments in the research and development of cell therapies, stringent regulations and an increasing number of human chronic diseases. On the other hand, Europe will also dominate the market during the forecast period due to advancements in the biopharmaceutical field and stringent regulations. The Asia-Pacific market is expected to grow faster in the future due to the growing cell therapy manufacturing industries and the adoption of new technologies.

Major key players in the cell therapy packaging products and services market areAlmac, Catalent Pharma Solutions, Cryoport Systems, Core Cryolab Inc., Yourway, Lufthansa Cargo, Saint-Gobain Life Sciences, Thermo Fisher Scientific, Sharp, West Pharmaceutical Services, Chart Industries Inc., and Other Prominent Players. Leading manufacturers in this field focus on novel therapy innovations, partnerships, collaborations, mergers, and agreements. These strategies will help to boost their growth opportunities in this market.

Key Developments:

Curious about this latest version of report? Enquire Before Buying @https://www.insightaceanalytic.com/enquiry-before-buying/1265

Market Segments

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Therapy

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Package Engineering Design

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Scale of Operation

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region

North America cell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

Europe cell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

Asia Pacific cell therapy packaging products and services market revenue (US$ Million) by Country,2022 to 2030

Latin Americacell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

Middle East & Africa cell therapy packaging products and services market revenue (US$ Million) by Country, 2022 to 2030

For Customized Information @ https://www.insightaceanalytic.com/customisation/1265

Other Related Reports Published by InsightAce Analytic:

Global Cell and Gene Therapy Bioassay Services Market

Global Vaccine Cold Chain Logistics Market

Global Cell and Gene Therapy Drug Delivery Devices Market

Why should buy this report:

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact US:

InsightAce Analytic Pvt. Ltd. Tel.: +1 718 593 4405 Email:info@insightaceanalytic.com Site Visit:www.insightaceanalytic.com Follow Us on LinkedIn @bit.ly/2tBXsgS Follow Us OnFacebook@bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

SOURCE InsightAce Analytic Pvt. Ltd.

See the article here:
Cell Therapy Packaging Products and Services Market worth $1.25 Billion by 2030 - Exclusive Report by Ins - Benzinga

Novartis five-year Kymriah data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL -…

By Stem Cell Treatment

Basel, June 12, 2022 Novartis today announced long-term results from the ELIANA pivotal clinical trial of Kymriah (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), with a maximum survival follow-up of 5.9 years. For the 79 patients treated with Kymriah in this study, the five-year overall survival (OS) rate was 55% (95% CI, 43-66), while the median event-free survival (EFS) for patients in remission within three months of infusion (n=65) was 43.8 months. These findings demonstrate the curative potential of Kymriah, the only CAR-T cell therapy available for these patients who previously had limited treatment options. These data were presented as an oral presentation during the 2022 European Hematology Association (EHA) Hybrid Congress (Abstract #S112)1.

These data mark a moment of profound hope for children, young adults and their families with relapsed or refractory B-cell ALL, as relapse after five years is rare, said Stephan Grupp, MD, PhD, Section Chief of the Cellular Therapy and Transplant Section, and Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy at Children's Hospital of Philadelphia (CHOP). Since the approval of Kymriah nearly five years ago, we have been able to offer a truly game-changing option to patients who previously faced a five-year survival rate of less than 10 percent.

This long-term follow up of ELIANA demonstrated the potential for Kymriah to transform cancer treatment in pediatric and young adult patients with r/r B-cell ALL, significantly improving outcomes with durable responses and a consistent safety profile in this patient population1:

At Novartis, we strive for cures. With nearly six-year follow-up data in these pediatric and young adults treated for B-cell ALL, we have our strongest evidence yet that one-time treatment with Kymriah has curative potential, said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development. These results strengthen our confidence in CAR-T cell therapies as a truly transformative and paradigm-shifting advance in cancer care, as well as our commitment to continue developing this technology with next-generation platforms.

Additional updates on the Novartis CAR-T program presented at the 2022 EHA Congress include new data from more patients and longer follow-up from the first-in-human dose-escalation trials with YTB323 in adults with r/r diffuse large B-cell lymphoma and PHE885 in adults with r/r multiple myeloma, the first Novartis CAR-T cell therapies developed using the Novartis T-Charge platform2,3,4. Visit https://www.hcp.novartis.com/virtual-congress/eha-2022/ to learn more about these data and our ongoing commitment to reimagining cancer care with CAR-T cell therapies.

About Kymriah Kymriah is the first-ever FDA-approved CAR-T cell therapy. It is a one-time treatment designed to empower patients immune systems to fight their cancer. Kymriah is currently approved for the treatment of r/r pediatric and young adult (up to and including 25 years of age) acute lymphoblastic leukemia (ALL), r/r adult diffuse large B-cell lymphoma (DLBCL) and r/r adult follicular lymphoma1.

About the ELIANA Trial ELIANA was the first pediatric global CAR-T cell therapy registration trial, examining patients in 25 centers in 11 countries across the US, Canada, Australia, Japan and the EU, including: Austria, Belgium, France, Germany, Italy, Norway and Spain. The trial was an open-label, multicenter, single-arm, global Phase II trial investigating the efficacy and safety of Kymriah in pediatric and young adult patients in r/r B-cell ALL who were primary refractory, chemorefractory, relapsed after, or were not eligible for allogeneic stem cell transplantation (SCT). The primary endpoint was overall remission rate (ORR), defined as best overall response of CR or CR with incomplete blood count recovery (CRi) within 3 months and maintained for 28 day. The secondary endpoints include CR/CRi with undetectable minimal residual disease (MRD), duration of remission, event-free survival, overall survival, cellular kinetics and safety5.

About T-Charge T-Charge is a next-generation CAR-T platform, innovated at the Novartis Institutes for BioMedical Research (NIBR), that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. By implementing the T-Charge platform, we aim to revolutionize CAR-T cell therapy with new products that have the potential to offer patients a higher likelihood of better and more durable responses, improved long-term outcomes and a reduced risk of severe adverse events. The T-Charge platform preserves T cell stemness (T cell ability to self-renew and mature), an important T cell characteristic closely tied to its therapeutic potential, which results in a product containing greater proliferative potential and fewer exhausted T cells. With T-Charge, CAR-T cell expansion occurs primarily within the patients body (in-vivo), eliminating the need for an extended culture time outside of the body (ex-vivo). The T-Charge platform, which implements important process efficiencies, will be rapid, compared with traditional CAR-T, and reliable, through simplified processes and streamlined quality control. Multiple CAR-T therapies, including YTB323 and PHE885, are being developed using the Novartis T-Charge platform.

About Novartis commitment to Oncology Cell Therapy As part of the unique Novartis strategy to pursue four cancer treatment platforms radioligand therapy, targeted therapy, immunotherapy and cell and gene therapy we strive for cures through cell therapies in order to enable more patients to live cancer-free. We will continue to pioneer the science and invest in our manufacturing and supply chain process to further advance transformative innovation.

Novartis was the first pharmaceutical company to significantly invest in pioneering CAR-T research and initiate global CAR-T trials. Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, is the foundation of the Novartis commitment to CAR-T cell therapy.

We have made strong progress in broadening our delivery of Kymriah, which is currently available for use in at least one indication in 30 countries and at more than 370 certified treatment centers, with clinical and real-world experience from administration to more than6,900 patients. We continue to pioneer in cell therapy, leveraging our vast experience to develop next-generation CAR-T cell therapies. These therapies will utilize our new T-Charge platform being evaluated to expand across hematological malignancies and bring hope for a cure to patients with other cancer types.

Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more athttps://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews For Novartis multimedia content, please visit https://www.novartis.com/news/media-library For questions about the site or required registration, please contact [emailprotected]

References

# # #

Novartis Media Relations E-mail: [emailprotected]

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: [emailprotected]

Here is the original post:
Novartis five-year Kymriah data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL -...

These are the non-surgical facelift treatments to consider for glowing skin – VOGUE India

By Stem Cell Treatment

As eerily relevant as 1992s Death Becomes Her is in 2022, there is an unexpected difference. Unlike Madeline (Meryl Streep) and Helen (Goldie Hawn), we arent hiding our facelifts. Instead, some of us are live streaming the whole experience. Dermal fillers and Botox are getting as common as getting a facial in your local salon.

"There has been a shift of mindset and increased acceptability of these procedures, says Dr Madhuri Agarwal of Yavana Aesthetics, Mumbai. In the next few years, the trend is going to be more innovations and better delivery mechanisms of these minimally invasive procedures that deliver long term, healthy skin.

What you want to do to look and feel good is not up for discussion. While lasers and acids are wonderful for skin texture and even tightening, a non-surgical facelift involving needles can be more effective for the latter. For example, filler that is more natural looking, because a laser isnt doing anything to make up for the lost volume.

Our bodies are dynamic and need maintenance as we age. Even, and especially, our facial skin. But with so many options of non-surgical face lifts available, it can be overwhelming to make a choice. We spoke to a few dermatologists to help break down the details of the best non-surgical facelift treatments involving needles.

Botox involves injecting a very safe neurotoxin called Botulinum to freeze muscles, and relax them, ironing out wrinkles. Wary but curious first timers can choose to start with very minute unitsthey wont erase all wrinkles but will smoothen them out enough to look a little more natural. I suggest this only when fine lines form, says Dr Kiran Sethi, a dermatologist based in Delhi and author of Skin Sense. It lasts 3-6 months, and there isnt much downtime. Its great when combined with fillers or skin boosters. Theres also been a focus on preventive Botox. If you get it done before the lines set in, you will have fewer lines as you age, explains Dr Geetika Mittal Gupta of ISAAC Luxe Clinic in Mumbai and Delhi. You will need less and less Botox as you age, because those muscles are not contracting as much. And by early I mean, when you see certain lines of ageing.

Fillers are usually injections of hyaluronic acid that add back lost volume to parts of your face. The Indian bone structure is such that our cheekbone is a little flat on the centre part of the face, explains Dr. Chytra V Anand, founder, Kosmoderma located in Chennai and Bengaluru. So most Indians, even teenagers, get dark circles and hollows. Its a loss of volume. So you have to put a filler in there. And people are accepting of that. Its not because they want to look like someone else, or they want to look younger. They just want to maintain their body and skin. The down time for fillers is usually 2-7 days, depending on how easily you bruise. And a good treatment can last anywhere between 1 and 2 years.

The vampire facial might have shocked people a few years ago, but today its one of the most popular treatments in India. Platelet-rich plasma is extracted from your blood, rich in growth hormones that renews blood flow and tissue regeneration wherever it is injected back, including your scalp. Its usually a course of 3-4 sessions, monthly, says Dr Sethi. It treats melasma, dehydration, has a mild filler effect too. And when used on the scalp, new hair growth can show in 6 months.

Theres also stem cell therapy for hair and skin rejuvenation. We take a small biopsy of the skin, splice the cells, and use the extract for regenerative therapy, says Dr Anand. It takes less time and commitment than PRP and is great for scar healing.

Its good to remember that these treatments are addictive too, says Dr Akber Aimer, Director of Aesthetic Medicine, Maya Medi Spa. You need to understand your limit. Always look for a good doctor who is experienced and talk about your problems and ask their opinions. Understand everything clearly. Your decision-making is a multi-step procedure. You need to have done proper research on the materials used and the treatment. Understand the technology. Trust your gut. And dont forget to ask for before and after pictures!

LED light therapy can help you achieve your skincare goals

In-clinic skincare treatments: How theyve evolved with the lockdowns

Here's how to get glowing skin for the summer, according to experts

Go here to read the rest:
These are the non-surgical facelift treatments to consider for glowing skin - VOGUE India

Local Father Battling Cancer to Host Blood Stem Cell Drive at SH Sprint Triathlon – The Hudson Indy Westchester’s Rivertowns News – – The Hudson…

By Stem Cell Medicine

Eugene Doherty is a local fire captain and father of a nine-year-old daughter.

June 9, 2022

By Rick Pezzullo

A local fire department captain is on a mission to register potential stem cell donors to help others like himself who have been stricken with cancer.

Eugene Doherty, 46, is battling acute lymphoblastic leukemia (ALL) but was fortunate enough to find a matching donor in his family, which is not often the case for 70 percent of people suffering from blood-related illnesses who must seek a match from a stranger to save their life.

Originally from Ireland, Doherty resides in Sleepy Hollow and has volunteered for 12 years with the Sleepy Hollow Sprint Triathlon. Prior to his diagnosis, he was an active triathlete.

This weekend, Doherty is teaming up with DKMS, the worlds largest blood stem cell donor center, at Kingsland Point Park at 299 Palmer Ave. in Sleepy Hollow to try to register potential donors.

Anyone in good health between the ages of 18 and 55 is encouraged to attend. Potential registrants will review medical eligibility, fill out a registration form, swab the insides of their cheeks, and return their completed packet before leaving the drive. Anyone who cannot attend the registration drives can register by ordering a free swab kit viahttps://www.dkms.org/get-involved/virtual-drives/sleepy-hollow-sprint-triathlon-donor-drive.

The registration drive will take place Saturday, June 11 from 9 to 11 a.m. and Sunday, June 12 from 7 a.m. to noon.

Advertisement

June 9, 2022

By Rick Pezzullo--- A local fire department captain is on a mission to register potential stem cell donors to help...

June 8, 2022

Westchester Power - the energy supplier set up by Sustainable Westchester that supplies electricity at a fixed, negotiated rate to...

June 6, 2022

June Events @ Your Library Tuesday, June 7 at 7 pm/Join landscape curator,Kate Kerinfor a virtual tour ofInnisfree Gardenand a...

June 4, 2022

By Barrett Seaman-- It was three-and-a-half years ago when entrepreneur Richelieu Dennis strolled through a packed Irvington trustee meeting room...

June 2, 2022

A brain cancer diagnosis last year finally forced Detective Dave Walsh to retire in February after two decades with the...

June 2, 2022

by Brad Ogden The Main Street School Lawn in Irvington will transform into a fun-filled, open air concert venue as...

May 31, 2022

The County Executive has announced that the Countys free rides program will begin on June 1, 2022 and run through...

May 31, 2022

By Barrett Seaman-- A cloudless sky and temperatures near ninety made it just a touch more difficult to focus on...

May 29, 2022

By Robert Kimmel-- Contributions from the Rotary Club of the Tarytowns can come in big packages or small ones. Atop...

May 27, 2022

By Shana Liebman-- One of the years most illuminating documentaries opens today: Feed the People profiles superhero-chef Jos Andrs and...

Read the original here:
Local Father Battling Cancer to Host Blood Stem Cell Drive at SH Sprint Triathlon - The Hudson Indy Westchester's Rivertowns News - - The Hudson...

Ambys Medicines to Present Data from Universal Human Hepatocyte Program at the 2022 ISSCR Annual Meeting – Galveston County Daily News

By Stem Cell Medicine

Country

United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Read this article:
Ambys Medicines to Present Data from Universal Human Hepatocyte Program at the 2022 ISSCR Annual Meeting - Galveston County Daily News

Expression of stem cell biomarkers Bmi1 and KLF4 in osteosarcoma and its clinical significance – Newswise

By Stem Cell Medicine

Abstract:

Objective To observe the expression of osteosarcoma stem cell biomarkers Bmi1 and KLF4 in osteosarcoma tissues and explore their value in the diagnosis, treatment and prognosis of osteosarcoma.

Methods Using retrospective research methods, 51 patients (28 males and 23 females) with osteosarcoma who were surgically resected and diagnosed by pathology in the Second Hospital of Shanxi Medical University from October 2009 to July 2019 were used as the experimental group. The age of cases varies from 10 to 67 (average 27.04) years old, and bone tissues adjacent to the tumor were taken from 10 samples as the normal control group. Immunohistochemical method was used to assess the expression levels of Bmi1 and KLF4 in 51 patients with osteosarcoma and 10 cases of paraneoplastic bone tissue specimens. Chi-square test was applied to analyze the relationship between the expression of Bmi1 and KLF4 and the clinical pathological data of patients. Correlation analysis was analyzed by the number of connections. The survival rate of patients was calculated by the Kaplan-Meier method. The log rank univariate analysis and Cox regression multivariate analysis were carried out to evaluate the prognostic value.

Results The positive expression rates of Bmi1 and KLF4 in the osteosarcoma group were 78.43% (40/51) and 80.39% (41/51), respectively, and in the bone tissue group were both 3/10. The difference of the positive expression rates of Bmi1 and KLF4 in the osteosarcoma group and bone tissue group was statistically significant (P < 0.05). In osteosarcoma group, the expression levels of Bmi1 and KLF4 were positively correlated (R = 0.399, P < 0.01). Bmi1 protein-positive, KLF4 protein-positive, and Bmi1 and KLF4 protein double-positive expression were statistically significant in Enneking surgical staging, lung metastasis, and pathological typing (all P < 0.05), but there was no statistically significant difference between different ages, genders, local recurrences, and tumor sizes (all P > 0.05).

Conclusion The expression of Bmi1 and KLF4 in osteosarcoma tissue was significantly higher than that in surrounding bone tissues, and their positive expression is a risk factor for the prognosis of patients with osteosarcoma.

Read this article:
Expression of stem cell biomarkers Bmi1 and KLF4 in osteosarcoma and its clinical significance - Newswise

Bridge Therapy For Neuroblastoma: A Game-Changing Paediatric Cancer Treatment | TheHealthSite.com – TheHealthSite

By Stem Cell Medicine

Patients Suffering From Neuroblastoma May Benefit From Bridge Therapy

Written by Kinkini Gupta | Updated : June 9, 2022 12:31 PM IST

Neuroblastoma, a pediatric cancer that arises from immature nerve cells has a very high risk of recurrence among approximately half of the children who are already suffering from cancer. With ever-advancing medicine and technology, researchers however have discovered a new therapy called the 'bridge therapy.' A study conducted and published the journal Cancer states that patients suffering from neuroblastoma may benefit from this therapy between induction and consolidation treatments. Neuroblastoma can often be cured by surgical removal of tumors followed by chemotherapy. These patients often receive induction therapy composed of various drugs used to carry out chemotherapy and surgery. This is followed by consolidation therapy, which involves a high-dose chemotherapy and stem cell transplants. Unfortunately, these treatments, which are currently in use, have not been successful in many children.

This newly discovered therapy will include immunotherapy drugs that have demonstrated anti-neuroblastoma activity in combination with chemotherapy, radiolabeled MBIG or combinations of chemotherapeutic agents. Research suggests that this therapy could offer some benefit to cancer patients. To examine the effectiveness of this therapy, a study including the data from 201 patients diagnosed with neuroblastoma at various hospitals from 2008-2018 were taken into consideration. Some patients were treated in three groups with different approaches based on physician, institutional or family preferences. The three steps were:

This study was especially done to find out if patients are responding well to bridge therapy prior to consolidation with stem cell transplant. They found out that the following results with patients who directly underwent consolidation:

Response to induction therapy is known to increase survival rate, and the study suggests that bridge therapy prior to consolidation therapy benefits patients with high-risk neuroblastoma with a poor response to induction. Also, response to bridge therapy prior to consolidation therapy is associated with outcome, and patients with less than a partial response may benefit from alternative treatment approaches. An accompanying editorial discusses the findings and agrees that future studies of bridge therapy for patients who do not experience a favorable response following standard induction therapy are needed.

Follow us on

Link:
Bridge Therapy For Neuroblastoma: A Game-Changing Paediatric Cancer Treatment | TheHealthSite.com - TheHealthSite

This Key Protein Is Essential for Brain Cell Longevity and Growth – SciTechDaily

By Adult Stem Cells

Recent research finds that the insulin receptor protein (INSR) is pivotal for brain stem cell longevity and growth.

Stem cells are the bodys raw materials they are the cells that give rise to all other cells with specialized functions. In the right circumstances, stem cells in the body divide to produce new cells known as daughter cells.

Humans contain neural stem cells in their brains. These brain stem cells may develop into neurons, astrocytes, or oligodendrocytes. Because neural stem cells generate all of the brains cell types, there is a multitude of stem cells in an embryos brain. In fact, the majority of brain cells are born in the embryo stage. These cells persist till adulthood and can be found in particular regions of the brain. Neural stem cells are essential for your brain to properly function.

According to research from Rutgers University, a receptor that was first identified as necessary for insulin action and is also found on neural stem cells found deep in the brains of mice is crucial for brain stem cell longevity, a finding that has important implications for brain health and future therapies for brain disorders.

The research, published in the journal Stem Cell Reports, focuses on a particular protein known as the insulin receptor (INSR), which is prevalent in neural stem cells in the brains subventricular zone. Neural stem cells give rise to the entire nervous system throughout development and persist into adulthood. Over the course of a persons life, these neural stem cells generate new neurons and non-neuronal cells that help the brains infrastructure and function.

Separately, while studying brain tumors, the researchers discovered that INSR plays an important role in the survival and maintenance of a population of specialized brain cancer cells known as glioblastoma (GBM) stem cells. They were able toreducethe growth of those primitive tumor-forming cells by inactivating the INSR in GBM stem cells.

Its important to understand the molecular mechanisms that are critical for the growth and sustenance of the brains stem cells under normal and abnormal growth states, said study author Steven Levison, a professor of neuroscience in the Department of Pharmacology, Physiology, and Neuroscience and director of the Laboratory for Regenerative Neurobiology at Rutgers New Jersey Medical School. Comprehending the signals that regulate these primitive cells could one day lead to new therapeutics for brain disorders.

Many neurodegenerative disorders, such as multiple sclerosis, Parkinsons disease, and Alzheimers disease, are connected with the destruction of brain cells, said co-author Teresa Wood, a Distinguished Professor and Rena Warshow Endowed Chair in Multiple Sclerosis in the Department of Pharmacology, Physiology, and Neuroscience at Rutgers New Jersey Medical School.

If we could influence how brain stem cells function then we can use this knowledge to replace diseased or dead brain cells with living ones, which would advance the treatment of neurological diseases and brain injuries, said Wood, who also teaches and conducts research at the Cancer Institute of New Jersey.

Cell receptors such as INSR are protein molecules that reside on the surfaces of cells. Substances, either natural or human-made, that open the lock of a receptor can spur a cell to divide, differentiate or die. By identifying which receptors perform these functions on specific cell types, and by understanding their structures and functions, scientists can design substances that act as keys to receptors, to turn them on or off.

Previous studies by this research team had shown that a certain key, the signaling protein that is known as the insulin-like growth factor-II (IGF-II), was necessary to maintain the neural stem cells in the two places of the adult brain that harbor these primitive cells. In the current experiment, scientists were looking to identify the receptor. To do so, they used genetic tools that allowed them to both delete the INSR and introduce a fluorescent protein so they could track the neural stem cells and the cells they generate. They found that the numbers of neural stem cells in the subventricular zone in the brains of mice lacking the INSR collapsed.

Adult neurogenesis the idea that new cells are produced in the adult brain has been a burgeoning field of scientific inquiry since the late 1990s, when researchers confirmed what had only been a theory in lab studies of human, primate, and bird brains. Neural stem cells in the adult are stem cells that can self-renew and produce new neurons and the supporting cells of the brain, oligodendrocytes, and astrocytes.

Given the widespread interest in stem cells as well as interest in whether alterations to adult stem cells might contribute to cancer, our research findings should be of interest, Levison said.

Other Rutgers authors included Shravanthi Chidambaram, Fernando J. Velloso, Deborah E. Rothbard, Kaivalya Deshpande, and Yvelande Cajuste of the Department of Pharmacology, Physiology, and Neuroscience at Rutgers New Jersey Medical School. Other participating investigators were at the University of Minnesota, the Albert Einstein College of Medicine, and Brown University.

Reference: Subventricular zone adult mouse neural stem cells require insulin receptor for self-renewal by Shravanthi Chidambaram, Fernando J. Velloso, Deborah E. Rothbard, Kaivalya Deshpande, Yvelande Cajuste, Kristin M. Snyder, Eduardo Fajardo, Andras Fiser, Nikos Tapinos, Steven W. Levison and Teresa L. Wood, 5 May 2022, Stem Cell Reports.DOI: 10.1016/j.stemcr.2022.04.007

See the original post here:
This Key Protein Is Essential for Brain Cell Longevity and Growth - SciTechDaily

The Many Spheres in Which CO2 Chambers Show Their Strengths – MedicalExpo e-Magazine

By Adult Stem Cells

Without CO2 incubators, there would be no coronavirus vaccines today. They are also absolutely essential for cancer research. These multiple uses help save lives and cure many different diseases. We would now like to introduce you to some of the interesting facets of CO2 incubators.

Sponsored by BINDER GmbH.

CO2 incubators are being used to conduct research in laboratories across the globe. The Bioscience Institute Middle East, which is among the worlds leading centers for regenerative medicine, is also using an incubator to process the bodys own cells as well as for plastic surgery applications.

The cellswhich are multiplied in an incubatorare also used in tissue repair as well as for orthopedic and dermatological treatments. The Bioscience Institute only uses skin and fat tissue specimens from adult (mature) cells. Using the bodys owni.e., autologouscells eliminates the risk of rejection while also preventing the complication of graft-versus-host disease (an unwanted reaction of the donors immune cells).

To be even more specific: the CO2 incubators are predominantly used to incubate stem cells from mesenchyme tissue (undifferentiated connective tissue).

Here is how it works: first, cells are extracted from fat tissue. This process is performed by means of enzymatic disaggregation (separation) using various steps of filtration and centrifugation. The crucial stage here is the expansion, i.e., extracting as many stem cells as possible, which is why it is absolutely essential to create the best possible growth conditions.

Dr. Simona Alfano, a biologist at the Bioscience Institute, explained:

When incubating the cells, it is vitally important for the selected parameters to remain exactly constant across all levels.

And this is precisely where the CO2 chambers from BINDER come into their ownwith their reproducible growth conditions, constant climatic conditions, low risk of contamination and high level of safety.

Find out more about why the ph value is a key factor in cell and tissue cultures.

CO2 chambers also played an important role during the coronavirus pandemic: firstly, in the development of coronavirus vaccines and, secondly, to test drugs that may be used to treat COVID-19 on cells.

For this work, the major pharmaceutical companies required huge volumes of cellswhich they were able to acquire with the aid of an incubator. The newly developed active ingredients were then tested using the cells.

The new vaccines used in the fight against the coronavirus were also repeatedly tested on cells in laboratories and evaluated. An incubator proved to be an essential piece of equipment in a laboratoryparticularly during the coronavirus pandemic.

Read more on premium equipment for virus research.

The Institute of Medical Engineering at the Lucerne University of Applied Sciences and Arts has been carrying out research in the field of space biology. The research team, led by Dr. Fabian Ille, is assisted in its work by a CO2 chamber.

Cells from a bovine hoof are being incubated inside the cabinet at regular intervals until they are needed for a specific experiment. Recently, the cells were frozen and taken to the French city of Bordeaux by Dr. Simon West and a team of researchers.

The reason behind this trip was that the research team in Lucerne was selected by the European Space Agency (ESA) to take part in parabolic flights over the Atlantic. Shortly before the parabolic flights, which lasted for a total of three hours, the cells were removed from the incubator and moved to flight hardware that had been prepared specifically for this purpose and was under controlled temperature conditions.

The scientists from Lucerne wanted to use the parabolic flights to investigate how the cells respond and adapt to mechanical forces. These findings will help them in future attempts to cultivate cartilage that is of a stronger and better consistency, for example. In other words, it might be possible to remove cells from a patient, reproduce them with this innovative new method, and then use them again in the treatment of human patients.

Weightless conditions are helping us to make significant progress, said Dr. Ille, reflecting on the research project so far.

In laboratory tests that have already been carried out, West and Ille have been able to demonstrate in very broad terms that this process could work in the future.In these tests, weightless conditions were simulated using a random position machine. Here again, a CO2 chamber from BINDER was used.

Safety is the absolute top priority here.180C sterilization ensures, for example, that every trial series begins with a clean and fully sterile incubator. Whats more, the fanless design means that germs are not stirred up.

The result is optimal cell growth and absolutely no contamination from airborne germs. A deep-drawn inner chamber without corners or edges also enables the incubator to be cleaned thoroughly with ease. It is therefore no surprise that major pharmaceutical manufacturers choose specifically to put their trust in CO2 incubators from BINDER.

BINDER CO2 incubators are the perfect combination of a range of solutions180C hot air sterilization, rapid control, fixture-free interiors and absolutely zero consumables. For optimal cell growthsafe, reliable, smart, economicallook no further than BINDER.

Originally posted here:
The Many Spheres in Which CO2 Chambers Show Their Strengths - MedicalExpo e-Magazine

‘Ghost heart’: Built from the scaffolding of a pig and the patient’s cells, this cardiac breakthrough may soon be ready for transplant into humans -…

By Adult Stem Cells

"It actually changed my life," said Taylor, who directed regenerative medicine research at Texas Heart Institute in Houston until 2020. "I said to myself, 'Oh my gosh, that's life.' I wanted to figure out the how and why, and re-create that to save lives."

That goal has become reality. On Wednesday at the Life Itself conference, a health and wellness event presented in partnership with CNN, Taylor showed the audience the scaffolding of a pig's heart infused with human stem cells -- creating a viable, beating human heart the body will not reject. Why? Because it's made from that person's own tissues.

"Now we can truly imagine building a personalized human heart, taking heart transplants from an emergency procedure where you're so sick, to a planned procedure," Taylor told the audience.

"That reduces your risk by eliminating the need for (antirejection) drugs, by using your own cells to build that heart it reduces the cost ... and you aren't in the hospital as often so it improves your quality of life," she said.

Debuting on stage with her was BAB, a robot Taylor painstakingly taught to inject stem cells into the chambers of ghost hearts inside a sterile environment. As the audience at Life Itself watched BAB functioning in a sterile environment, Taylor showed videos of the pearly white mass called a "ghost heart" begin to pinken.

"It's the first shot at truly curing the number one killer of men, women and children worldwide -- heart disease. And then I want to make it available to everyone," said Taylor to audience applause.

"She never gave up," said Michael Golway, lead inventor of BAB and president and CEO of Advanced Solutions, which designs and creates platforms for building human tissues.

"At any point, Dr. Taylor could have easily said 'I'm done, this just isn't going to work. But she persisted for years, fighting setbacks to find the right type of cells in the right quantities and right conditions to enable those cells to be happy and grow."

"We were putting cells into damaged or scarred regions of the heart and hoping that would overcome the existing damage," she told CNN. "I started thinking: What if we could get rid of that bad environment and rebuild the house?"

Soon, she graduated to using pig's hearts, due to their anatomical similarity to human hearts.

"We took a pig's heart, and we washed out all the cells with a gentle baby shampoo," she said. "What was left was an extracellular matrix, a transparent framework we called the 'ghost heart.'

"Then we infused blood vessel cells and let them grow on the matrix for a couple of weeks," Taylor said. "That built a way to feed the cells we were going to add because we'd reestablished the blood vessels to the heart."

The next step was to begin injecting the immature stem cells into the different regions of the scaffold, "and then we had to teach the cells how to grow up."

"We must electrically stimulate them, like a pacemaker, but very gently at first, until they get stronger and stronger. First, cells in one spot will twitch, then cells in another spot twitch, but they aren't together," Taylor said. "Over time they start connecting to each other in the matrix and by about a month, they start beating together as a heart. And let me tell you, it's a 'wow' moment!"

But that's not the end of the "mothering" Taylor and her team had to do. Now she must nurture the emerging heart by giving it a blood pressure and teaching it to pump.

"We fill the heart chambers with artificial blood and let the heart cells squeeze against it. But we must help them with electrical pumps, or they will die," she explained.

The cells are also fed oxygen from artificial lungs. In the early days all of these steps had to be monitored and coordinated by hand 24 hours a day, 7 days a week, Taylor said.

"The heart has to eat every day, and until we built the pieces that made it possible to electronically monitor the hearts someone had to do it person -- and it didn't matter if it was Christmas or New Year's Day or your birthday," she said. "It's taken extraordinary groups of people who have worked with me over the years to make this happen."

But once Taylor and her team saw the results of their parenting, any sacrifices they made became insignificant, "because then the beauty happens, the magic," she said.

"We've injected the same type of cells everywhere in the heart, so they all started off alike," Taylor said. "But now when we look in the left ventricle, we find left ventricle heart cells. If we look in the atrium, they look like atrial heart cells, and if we look in the right ventricle, they are right ventricle heart cells," she said.

"So over time they've developed based on where they find themselves and grown up to work together and become a heart. Nature is amazing, isn't she?"

As her creation came to life, Taylor began to dream about a day when her prototypical hearts could be mass produced for the thousands of people on transplant lists, many of whom die while waiting. But how do you scale a heart?

"I realized that for every gram of heart tissue we built, we needed a billion heart cells," Taylor said. "That meant for an adult-sized human heart we would need up to 400 billion individual cells. Now, most labs work with a million or so cells, and heart cells don't divide, which left us with the dilemma: Where will these cells come from?"

"Now for the first time we could take blood, bone marrow or skin from a person and grow cells from that individual that could turn into heart cells," Taylor said. "But the scale was still huge: We needed tens of billions of cells. It took us another 10 years to develop the techniques to do that."

The solution? A bee-like honeycomb of fiber, with thousands of microscopic holes where the cells could attach and be nourished.

"The fiber soaks up the nutrients just like a coffee filter, the cells have access to food all around them and that lets them grow in much larger numbers. We can go from about 50 million cells to a billion cells in a week," Taylor said. "But we need 40 billion or 50 billion or 100 billion, so part of our science over the last few years has been scaling up the number of cells we can grow."

Another issue: Each heart needed a pristine environment free of contaminants for each step of the process. Every time an intervention had to be done, she and her team ran the risk of opening the heart up to infection -- and death.

"Do you know how long it takes to inject 350 billion cells by hand?" Taylor asked the Life Itself audience. "What if you touch something? You just contaminated the whole heart."

Once her lab suffered an electrical malfunction and all of the hearts died. Taylor and her team were nearly inconsolable.

"When something happens to one of these hearts, it's devastating to all of us," Taylor said. "And this is going to sound weird coming from a scientist, but I had to learn to bolster my own heart emotionally, mentally, spiritually and physically to get through this process."

Enter BAB, short for BioAssemblyBot, and an "uber-sterile" cradle created by Advance Solutions that could hold the heart and transport it between each step of the process while preserving a germ-free environment. Taylor has now taught BAB the specific process of injecting the cells she has painstakingly developed over the last decade.

"When Dr. Taylor is injecting cells, it has taken her years to figure out where to inject, how much pressure to put on the syringe, and the best speed and pace to add the cells," said BAB's creator Golway.

"A robot can do that quickly and precisely. And as we know, no two hearts are the same, so BAB can use ultrasound to see inside the vascular pathway of that specific heart, where Dr. Taylor is working blind, so to speak," Golway added. "It's exhilarating to watch -- there are times where the hair on the back of my neck literally stands up."

Taylor left academia in 2020 and is currently working with private investors to bring her creation to the masses. If transplants into humans in upcoming clinical trials are successful, Taylor's personalized hybrid hearts could be used to save thousands of lives around the world.

In the US alone, some 3,500 people were on the heart transplant waiting list in 2021.

"That's not counting the people who never make it on the list, due to their age or heath," Taylor said. "If you're a small woman, if you're an underrepresented minority, if you're a child, the chances of getting an organ that matches your body are low.

If you do get a heart, many people get sick or otherwise lose their new heart within a decade. We can reduce cost, we can increase access, and we can decrease side effects. It's a win-win-win."

Taylor can even envision a day when people bank their own stem cells at a young age, taking them out of storage when needed to grow a heart -- and one day even a lung, liver or kidney.

"Say they have heart disease in their family," she said. "We can plan ahead: Grow their cells to the numbers we need and freeze them, then when they are diagnosed with heart failure pull a scaffold off the shelf and build the heart within two months.

"I'm just humbled and privileged to do this work, and proud of where we are," she added. "The technology is ready. I hope everyone is going to be along with us for the ride because this is game-changing."

The rest is here:
'Ghost heart': Built from the scaffolding of a pig and the patient's cells, this cardiac breakthrough may soon be ready for transplant into humans -...

→←